Skip to main content

Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.

Canopy Rivers Inc. (RIV-T) said its investment portfolio company, Les Serres Vert Cannabis Inc., a joint venture with Canopy Growth Corp. (WEED-T; CGC-N) and Les Serres Stéphane Bertrand has received a licence amendment from Health Canada that significantly increases Vert Mirabel’s greenhouse production footprint.

“We are excited about the rapid progress being made at Vert Mirabel,” said Olivier Dufourmantelle, chief operating officer at Canopy Rivers. “This latest amendment is a testament to the strength of the licensing team at Canopy Growth Corporation, the operating pedigree of the local management team, and the quality of the greenhouse infrastructure.”

Story continues below advertisement

The Vert Mirabel joint venture was established in December 2017 between the Company, Canopy Growth and Mr. Bertrand.

**

MedMen Enterprises Inc. (MMEN-CN) said it signed a deal to acquire a licensed dispensary from Berkeley Patients Group in Emeryville, Calif. “As a result of the transaction, MedMen will have one of only two adult-use licenses issued in the City of Emeryville, just outside San Francisco,” the company said.

**

Partners Real Estate Investment Trust (PAR.UN-T) said it has agreed to sell its retail property in Cornwall, Ont. for $8.4-million. The transaction is not subject to either a financing condition or a due diligence condition, the trust stated.

**

Celestica, Inc. (CLS-N; CLS-T) said it plans to acquire Impakt Holdings, LLC., a manufacturer in the semiconductor and Organic Light Emitting Diode (OLED) display industries, for US$329-million.

Story continues below advertisement

"Through this acquisition, Celestica expects to gain significant, new capabilities in large-format, complex, high-mix manufacturing solutions for multiple industries, and broaden its precision component manufacturing, full system assembly, integration and machining capabilities," the company stated.

“The acquisition of Impakt will enhance Celestica’s position as the largest end-to-end capital equipment manufacturer in our industry,” said Rob Mionis, CEO, Celestica.

ICC International Cannabis Corp. (ICC-X) says has been granted a medical cannabis cultivation licence by the Greek government, superseding and augmenting its existing hemp license. “The licence grant is a conditional pre-approval for medical Cannabis cultivation in the Greek prefecture of Imathia,” the company stated.

ICC said it controls a 16-acre land package in northern Greece, which will be dedicated to medical grade cannabis cultivation, extraction, distribution, as well as research and development.

“Receipt of the first medical Cannabis cultivation licence to be issued by Greece represents a strong endorsement of the company's seed-to-sale initiatives globally, and in the EU in particular," stated CEO Eugene Beukman. "This is a material milestone for both the industry and the company, of which International Cannabis is very proud."

In connection with the transaction, ICC said it will pay US$200,000 in cash and will issue 12 million shares. It said a finders fee is payable on the transaction.

Story continues below advertisement

**

International Petroleum Corp. (IPCO-T) has a deal to buy BlackPearl Resources Inc. (PXX-T). The enterprise value of the deal is US$1.36-billion, including US#348-million in debt, the companies said.

The deal is based upon a share exchange ratio of 0.22 shares of IPC for each BlackPearl share. The acquisition remains subject to shareholder approvals of both IPC and BlackPearl and certain regulatory approvals.

"I am very excited about the future of IPC as the leading oil and gas growth company in the Lundin Group," stated Lukas Lundin, chairman of IPC. "IPC's strategy is to maximize the value of the current asset base and, at the same time, seek to use its financial strength to acquire strategic oil and gas assets. This is exactly the right time in the resource cycle to be pursuing this strategy."

**

MTY Food Group Inc. (MTY-T) reported third-quarter system sales of $787.9-million up from $634.9-million last year. Revenue came in at $91.2-million versus $72.4-million a year ago.

Story continues below advertisement

Net income was $22.3-million or 88 cents per share up from $12-million or 56 cents a year earlier.

"We are extremely pleased with our third quarter results with EBITDA marking a historical high for the company in a seasonally strong period," stated chief financial officer Eric Lefebvre. "Our results benefited from a strong performance from some of our recent acquisitions, more particularly Imvescor Restaurant Group and The Counter Custom Burgers, as well as cost control initiatives and operational leverage which together drove EBITDA margins to new levels."

Analysts were expecting revenue of $89.2-million and earnings of 70 cents per share in the latest quarter.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter